Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

A study to assess the safety of ARGX-121 in Healthy Adult Participants Ended

2025-521524-30-00 Healthy volunteers 1 2025-06-05
A study to investigate how different tablet types of balinatunfib and food will influence the absorption of balinatunfib in blood in healthy… Ended

2024-519860-41-00 Immune system diseases 3 2025-06-02
Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP Ended

2024-515386-34-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2025-05-29
A clinical trial to compare three oral treatments and a placebo in preventing skin reactions caused by histamine in healthy volunteers Ended

2024-516569-35-00 Allergy 6 2025-05-09
Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allerg… Ended

2024-517014-15-00 Moderate-to-severe allergic rhinitis / rhino-conjunctiv 10 2025-05-07
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of… Ended

2024-517814-13-00 Moderate to Severe Atopic Dermatitis 4 2025-04-30
A study to investigate the efficacy and safety of subcutaneous lunsekimig (SAR443765) compared with placebo in adult participants with moder… Ended

2024-511549-20-00 Dermatitis atopic 4 2025-04-22
A study to investigate the bioavailability of the SAR444656 test formulation and the food effect on the SAR444656 test formulation in health… Ended

2024-515621-28-00 Healthy Volunteer 3 2025-04-17
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in… Ended

2024-510826-16-00 Rheumatoid Arthritis 5 2025-04-07
A FIRST-IN-HUMAN PHASE I TRIAL OF OX118 IN HEALTHY VOLUNTEERS Ended

2024-515378-28-00 Immune system Diseases 1 2025-04-03
A trial in healthy participants to examine the safety, tolerability, and pharmacokinetics of orally administered FT751 Ended

2024-519998-19-00 Inflammatory diseases 1 2025-03-31
Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma Ended

2024-510972-19-00 Primary mediastinal large B-cell lymphoma (PMBCL) 4 2025-03-13
A clinical study of MK-2420 in healthy people (MK-2420-002) Ended

2024-516548-25-00 Rheumatoid arthritis 3 2025-03-12
A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT… Ended

2023-505908-28-00 Chronic spontaneous urticaria 2 2025-02-26
A PHASE-1, FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOL… Ended

2023-507504-31-00 Lupus erythematosus 1 2025-01-14
A Phase I, Open-Label, Randomized, Two-Period, Cross-Over Study in Healthy Subjects to Assess the Influence of a High-Calorie, High-Fat Meal… Ended

2024-518453-41-00 Hereditary angioedema (HAE) 3 2024-12-30
A clinical study of MK-2420 in healthy men (MK-2420-003) Ended

2024-518104-47-00 Rheumatoid arthritis 3 2024-12-19
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP118… Ended

2024-514981-37-00 Rheumatoid Arthritis 4 2024-12-05
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended

2023-507680-19-00 Sjögren’s Syndrome 4 2024-11-28
Phleum pratense and Dactylis glomerata allergen extracts. Determination of the in vivo histamine equivalent prick test units. Ended

2024-514215-98-00 Allergy to Phleum pratense and Dactylis glomerata. 4 2024-11-26
Safety Trial, DSC vs. BAT in SR acute GvHD Ended

2024-511768-97-01 Graft vs Host Disease 4 2024-11-20
PARADOX study Ended

2024-515278-28-00 ulcerative colitis 6 2024-11-15
Investigating the safety, feasibility, and optimal dose of risankizumab-800CW in IBD - NAVIGATE study Ended

2024-515358-25-00 Inflammatory Bowel Disease (IBD) 7 2024-11-08
Prospective and multicentre evaluation of 3 different doses of IV busulfan associated with fludarabine and thymoglobuline in the conditionin… Ended

2024-516435-27-00 High-risk myeloïd malignancies 4 2024-11-05